SAN DIEGO, CA -- (MARKET WIRE) -- August 29, 2006 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has been awarded a cGMP manufacturing contract to produce a DNA-based HIV-1 vaccine. The contract awarded by Advanced BioScience Laboratories, Inc. (ABL), a leader in the research, development, and manufacturing of retroviral disease products and services, is under a master agreement with the National Institutes of Health (NIH) and funded by the National Institute of Allergy and Infectious Diseases (NIAID). The funding for Althea’s production of the DNA HIV-1 vaccine totaling $911,549 is provided in its entirety by the National Institute of Allergy and Infectious Disease, NIH under Prime Contract No. HHSN266200400045C. The contract will support Althea’s efforts for plasmid DNA process development, vaccine production, purification, and regulatory documentation.
